Patents Assigned to Cardiff Oncology, Inc.
  • Cancer treatment using FGFR inhibitors and PLK1 inhibitors
    Patent number: 11957677
    Abstract: Provided include methods, compositions and kits for treating cancer in a subject. The method can comprise administrating an FGFR inhibitor (for example, AZD4547) and a PLK1 inhibitor (for example, onvansertib) to the subject in a manner sufficient to inhibit progression of the cancer.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: April 16, 2024
    Assignee: Cardiff Oncology, Inc.
    Inventors: Maya Ridinger, Mark Erlander, Anju Karki